Search - tctmd.com

Displaying 1 - 20 of 30

Sort: Relevancy | Date

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

News Daily News

New Risk Models Superior to Pretest Probability at Predicting CAD

Yael L. Maxwell

November 15, 2022

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

News Daily News

SCAD in Men: Canadian Study Sheds Light on Rare Condition

Caitlin E. Cox

October 25, 2022

News Conference News TCT 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Shelley Wood

September 22, 2022

Presentation TCT 2022

TCT 761: Multivessel Coronary Artery Thrombus in the Absence of Obstructive Coronary Atherosclerosis, a Potential Role for CCTA

Presenter: Brent Klinkhammer

September 18, 2022

Presentation TCT 2022

TCT 57: Everolimus-eluting Bioresorbable Vascular Scaffolds for Coronary Atherosclerosis Restoration Therapy: Insights on Long-term Intracoronary Imaging and Physiological Results of Bioresorption

Presenter: Gabriele Pesarini

September 17, 2022

News Conference News TCT 2022

Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus

Yael L. Maxwell

September 16, 2022

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

Todd Neale

August 28, 2022

News Conference News ESC 2022

ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention

Shelley Wood

August 27, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Daily News

Higher Subclinical Atherosclerosis in Black Americans Remains Unexplained

Yael L. Maxwell

July 15, 2022

News Opinion CV Team Dispatch

July 2022 News Roundup

L.A. McKeown

July 01, 2022

News Daily News

Lower 10-Year Mortality With Multiple Arterial CABG in Diabetes: ART

Yael L. Maxwell

June 28, 2022

News Conference News EAS 2022

Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively

Michael O'Riordan

May 27, 2022

News Conference News EAS 2022

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

Michael O'Riordan

May 26, 2022

News Conference News EAS 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Michael O'Riordan

May 26, 2022

News Conference News EAS 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

Michael O'Riordan

May 24, 2022

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

Advertisement

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

New Risk Models Superior to Pretest Probability at Predicting CAD

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

SCAD in Men: Canadian Study Sheds Light on Rare Condition

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

TCT 761: Multivessel Coronary Artery Thrombus in the Absence of Obstructive Coronary Atherosclerosis, a Potential Role for CCTA

TCT 57: Everolimus-eluting Bioresorbable Vascular Scaffolds for Coronary Atherosclerosis Restoration Therapy: Insights on Long-term Intracoronary Imaging and Physiological Results of Bioresorption

Primordial Prevention Before End-stage CVD: Experts Call for a Fresh Focus

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Higher Subclinical Atherosclerosis in Black Americans Remains Unexplained

July 2022 News Roundup

Lower 10-Year Mortality With Multiple Arterial CABG in Diabetes: ART

Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively

Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content